287 related articles for article (PubMed ID: 34102453)
1. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
2. Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Fröhlich A; Niebel D; Fietz S; Egger E; Buchner A; Sirokay J; Landsberg J
Cancer Immunol Immunother; 2020 May; 69(5):759-769. PubMed ID: 32052079
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
4. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
5. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
6. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
7. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
[TBL] [Abstract][Full Text] [Related]
8. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of immune checkpoint inhibitors for in-transit melanoma.
Nan Tie E; Lai-Kwon J; Rtshiladze MA; Na L; Bozzi J; Read T; Atkinson V; Au-Yeung G; Long GV; McArthur GA; Sandhu S; Saw R; Walpole E; Menzies A; Smithers M; Gyorki DE
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376722
[TBL] [Abstract][Full Text] [Related]
10. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
11. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
12. Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM; Karasek M; Koch L; Silmbrod R; Mangana J; Latifyan S; Aedo-Lopez V; Kehrer H; Weihsengruber F; Koelblinger P; Posch C; Kofler J; Michielin O; Richtig E; Hafner C; Hoeller C
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608376
[TBL] [Abstract][Full Text] [Related]
13. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
Garnock-Jones KP
BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
[TBL] [Abstract][Full Text] [Related]
14. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
[No Abstract] [Full Text] [Related]
15. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.
Stahlie EHA; Franke V; Zuur CL; Klop WMC; van der Hiel B; Van de Wiel BA; Wouters MWJM; Schrage YM; van Houdt WJ; van Akkooi ACJ
Cancer Immunol Immunother; 2021 Aug; 70(8):2291-2300. PubMed ID: 33507342
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
17. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.
Larocca CA; LeBoeuf NR; Silk AW; Kaufman HL
Am J Clin Dermatol; 2020 Dec; 21(6):821-832. PubMed ID: 32767272
[TBL] [Abstract][Full Text] [Related]
18. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
Dummer R; Gyorki DE; Hyngstrom J; Berger AC; Conry R; Demidov L; Sharma A; Treichel SA; Radcliffe H; Gorski KS; Anderson A; Chan E; Faries M; Ross MI
Nat Med; 2021 Oct; 27(10):1789-1796. PubMed ID: 34608333
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
Burke EE; Zager JS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]